Navigation Links
Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
Date:8/15/2012

SAN DIEGO, Aug. 15, 2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq:  TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three and six months ended June 30, 2012. Following its public offering in the second quarter, Trovagene has a cash balance of $9.3 million as of June 30, 2012, and is poised to further pursue its development programs in the following four diagnostic areas: cancer detection, transplant monitoring, infectious disease, and prenatal diagnostics.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

"We are continuing to execute our product development path at a significant pace," said Antonius Schuh, chief executive officer of Trovagene. "We expect to launch our first molecular diagnostic test for the detection of oncogene mutations in the urine of cancer patients by the end of the year."

Second Quarter Financial ResultsFor the second quarter ended June 30, 2012, Trovagene reported a loss of $3.436 million, or $0.28 per share, as compared to a loss of $0.458 million, or $0.05 per share, for the same period in 2011. The increase is primarily due to a loss of $2.18 million from the change in fair value of derivative instruments – warrants – during the second quarter of 2012 as compared to a gain of $.226 million in the prior year comparable period.

First Half Financial ResultsNet loss for the six months ended June 30, 2012 is $4.608 million or $0.40 per share, as compared to a loss of $1.020 million, or $0.11 per share for the six months ended June 30, 2011. The increase in net loss is primarily attributable to a loss of $2.213 million from the change in fair value of derivative instruments – warrants – during the six months ended June 30, 2012, as compared to a gain of $.423 million in the prior year comparable period.

Cash and Cash EquivalentsTrovagene had cash and cash equivalents of $9.3 million at June 30, 2012, as compared to $0.7 million at December 31, 2011. The increase in cash to $9.3 million is primarily the net result of cash provided by financing activities, including the net proceeds of $9.1 million received from an underwritten public offering of our common stock in June 2012.

Milestones

Review of Recent Announcements Demonstrates Progress

  • Strengthened Patent Portfolio
  • Received Notification of Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia on July 18, 2012
  • Received Notification of Issuance of European Patent for Detection of Pathogenic Infections on May 10, 2012
  • Improved Liquidity and Access to Capital
  • Completed Public Offering and began trading on NASDAQ on June 4, 2012
  • Added to the Russell Microcap Index on June 25, 2012
  • Expansion of KRAS Mutation Detection Development Program
  • Began Validation Program for transrenal KRAS Mutation Detection of Pancreatic Cancer on May 30, 2012
  • Commenced Study at MD Anderson Cancer Center for Transrenal KRAS Mutation Detection in Pancreatic Cancer on June 13, 2012
  • Expansion of High Risk HPV Carrier Screening Development Program
  • Initiated Program to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine on May 2, 2012
  • Signed Collaboration with Strand Life Sciences to Validate and Offer Urine-based HPV Screening Test in India and South Asia on June 7, 2012
  • Expanded Executive Management Team
  • Added sales and marketing executive Keith McCormick as Vice President, Commercial Operations on April 17, 2012
  • Added cancer geneticist Dr. Carlo Croce as scientific consultant and member of Scientific Advisory Board on May 1, 2012
  • Added Dr. Mark Erlander, chief scientific officer of bioTheranostics, as scientific consultant and member of Scientific Advisory Board on July 1, 2012
  • About Trovagene, Inc.

    Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. Trovagene has a strong patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in chronic lymphocytic leukemia (CLL) patients.

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.

    (Financial Information to Follow)ContactTrovagene, Inc.FinancialInvestor RelationsStephen Zaniboni

    Chief Financial OfficerAmy Caterina

    Investor RelationsTrovagene, Inc.Trovagene, Inc.858-952-7590858-952-7593szaniboni@trovagene.comacaterina@trovagene.com 

    Selected Financial Information

    Consolidated Condensed Statements of Operations

    (unaudited)

     (in thousands, except for per share amounts)Three Months EndedJune 30,Six Months EndedJune 30,2012201120122011Revenues$

    41$

    80$

    76$

    169Operating expenses:Research and development 477143815401General and administrative 8105841,6371,135Total operating expenses1,2877272,4521,536Loss from operations(1,246)(647)(2,376)(1,367)Other income (expense)-(28)-(57)Change in fair value of derivative instruments - warrants (2,181)226(2,213)423Net loss$

    (3,427)$

    (449)$

    (4,589)$

    (1,001)Preferred stock dividend(9)(9)(19)(19)Net loss available to common shareholders$

    (3,436)$

    (458)$

    (4,608)$

     

    (1,020)Basic and diluted net loss per share$

    (0.28)$

    (0.05) 

    $

    (0.40) 

    $

     

    (0.11)Weighted average shares outstanding12,0869,15211,5449,088 

    Consolidated Condensed Balance Sheet Information

    (in thousands)June 30,
    2012December 31,
    2011Cash and cash equivalents$

    9,304$

    700Other assets498316Property and equipment, net15023Total assets$

    9,952$

    1,039Accounts payable, accrued expenses and other liabilities$

    1,236$

    1,430Derivative financial instruments3,2273,840Stockholders' equity (deficiency)5,489(4,231)Total liabilities and stockholders' equity (deficiency)$

    9,952$

    1,039
    '/>"/>

    SOURCE Trovagene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
    2. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
    3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
    4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
    5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
    6. Misonix Announces New Distribution Agreement For Panama
    7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
    8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
    10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
    11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/8/2017)... 8, 2017   Responding to Heath Ledger,s ... death of singer Chris Cornell in May, the ... offers a free online psychiatric drug side ... families about psychotropic drug risks. The father ... from an accidental overdose, has called for tighter rules on ...
    (Date:6/7/2017)... June 7, 2017  Novavax, Inc., (Nasdaq: NVAX ... Phase 2 trials of its RSV F protein recombinant nanoparticle ... age have been published in the journal Vaccine ... shared in prior scientific conferences). The Company previously announced ... Novavax is developing the RSV F Vaccine with the goal ...
    (Date:6/5/2017)... Kohll,s Pharmacy & Homecare is the first distributor of ... . The Raizer is a simple battery operated mobile ... an almost-standing position within a few minutes. The ... and does not require any extra effort besides a ... can operate it, and lightweight and portable so ...
    Breaking Medicine Technology:
    (Date:6/27/2017)... ... June 27, 2017 , ... Today, June 27th is PTSD Awareness Day. Over ... 20% will receive adequate care due to lack of effective treatments, fear of stigma ... all. And left untreated, veterans are at an increased risk for self-destructive behavior, including ...
    (Date:6/27/2017)... ... ... Children’s National Health System received top honors in the 2017-18 U.S News & ... of more than 1500 neonatal intensive care units coast to coast. Children’s ... the top performing children’s hospitals in the country. , In addition to achieving ...
    (Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin ... Specialists, in collaboration with the Fertility Center of California, is pleased to announce ... epidydimal sperm aspiration) and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments ...
    (Date:6/26/2017)... Mexico (PRWEB) , ... June 26, 2017 , ... ... anorgasmia, and urinary leakage is revolutionizing the way women look and feel about ... tackling the problem of female sexual dysfunction and urinary leakage head on with ...
    (Date:6/26/2017)... ... 26, 2017 , ... KICKICO , a protocol built on Ethereum for ... many catastrophic issues within funding campaigns. KICKICO developers are testing the platform, which will ... the raising of funds through the power of many - has been around for ...
    Breaking Medicine News(10 mins):